EUR-Lex Access to European Union law
This document is an excerpt from the EUR-Lex website
Document 62018TA0337
Joined Cases T-337/18 and T-347/18: Judgment of the General Court of 15 September 2021 — Laboratoire Pareva and Biotech3D v Commission (Biocidal products — Active substance PHMB (1415; 4.7) — Refusal of approval for product-types 1, 5 and 6 — Conditional approval for product-types 2 and 4 — Risks to human health and the environment — Regulation (EU) No 528/2012 — Article 6(7)(a) and (b) of Delegated Regulation (EU) No 1062/2014 — Harmonised classification of the active substance under Regulation (EC) No 1272/2008 — Prior consultation of the ECHA — Manifest error of assessment — Read-across — Right to be heard)
Joined Cases T-337/18 and T-347/18: Judgment of the General Court of 15 September 2021 — Laboratoire Pareva and Biotech3D v Commission (Biocidal products — Active substance PHMB (1415; 4.7) — Refusal of approval for product-types 1, 5 and 6 — Conditional approval for product-types 2 and 4 — Risks to human health and the environment — Regulation (EU) No 528/2012 — Article 6(7)(a) and (b) of Delegated Regulation (EU) No 1062/2014 — Harmonised classification of the active substance under Regulation (EC) No 1272/2008 — Prior consultation of the ECHA — Manifest error of assessment — Read-across — Right to be heard)
Joined Cases T-337/18 and T-347/18: Judgment of the General Court of 15 September 2021 — Laboratoire Pareva and Biotech3D v Commission (Biocidal products — Active substance PHMB (1415; 4.7) — Refusal of approval for product-types 1, 5 and 6 — Conditional approval for product-types 2 and 4 — Risks to human health and the environment — Regulation (EU) No 528/2012 — Article 6(7)(a) and (b) of Delegated Regulation (EU) No 1062/2014 — Harmonised classification of the active substance under Regulation (EC) No 1272/2008 — Prior consultation of the ECHA — Manifest error of assessment — Read-across — Right to be heard)
OJ C 452, 8.11.2021, p. 18–19
(BG, ES, CS, DA, DE, ET, EL, EN, FR, HR, IT, LV, LT, HU, MT, NL, PL, PT, RO, SK, SL, FI, SV)
- Date of document:
- 15/09/2021
- Date lodged:
- 01/06/2018
- Author:
- General Court
- Form:
- Judicial information
- Authentic language:
- English
- Type of procedure:
- Action for annulment - unfounded
- Link
- Select all documents mentioning this document
- Case affecting:
-
- Related EU case-law document 62018TJ0337
- Instruments cited in case law:
- Link
- EUROVOC descriptor:
|
8.11.2021 |
EN |
Official Journal of the European Union |
C 452/18 |
Judgment of the General Court of 15 September 2021 — Laboratoire Pareva and Biotech3D v Commission
(Joined Cases T-337/18 and T-347/18) (1)
(Biocidal products - Active substance PHMB (1415; 4.7) - Refusal of approval for product-types 1, 5 and 6 - Conditional approval for product-types 2 and 4 - Risks to human health and the environment - Regulation (EU) No 528/2012 - Article 6(7)(a) and (b) of Delegated Regulation (EU) No 1062/2014 - Harmonised classification of the active substance under Regulation (EC) No 1272/2008 - Prior consultation of the ECHA - Manifest error of assessment - Read-across - Right to be heard)
(2021/C 452/17)
Language of the case: English
Parties
Applicant in cases T-337/18 and T-347/18: Laboratoire Pareva (Saint-Martin-de-Crau, France) (represented by: K. Van Maldegem, S. Englebert, P. Sellar and M. Grunchard, lawyers)
Applicant in case T-347/18: Biotech3D Ltd & Co. KG (Gampern, Austria) (represented by: K. Van Maldegem, S. Englebert, P. Sellar and M. Grunchard, lawyers)
Defendant: European Commission (represented by: R. Lindenthal and K. Mifsud-Bonnici, acting as Agents)
Interveners in support of the defendant: French Republic (represented by: A.-L. Desjonquères, J. Traband, E. Leclerc and W. Zemamta, acting as Agents), European Chemicals Agency (ECHA) (represented by: M. Heikkilä, C. Buchanan and T. Zbihlej, acting as Agents)
Re:
Applications pursuant to Article 263 TFEU seeking annulment of, in Case T 337/18, Commission Implementing Decision (EU) 2018/619 of 20 April 2018 not approving PHMB (1415; 4.7) as an existing active substance for use in biocidal products of product-types 1, 5 and 6 (OJ 2018 L 102, p. 21), and, in Case T 347/18, Commission Implementing Regulation (EU) 2018/613 of 20 April 2018 approving PHMB (1415; 4.7) as an existing active substance for use in biocidal products of product-types 2 and 4 (OJ 2018 L 102, p. 1).
Operative part of the judgment
The Court:
|
1. |
Joins Cases T-337/18 and T-347/18 for the purposes of the present judgment; |
|
2. |
Dismisses the actions; |
|
3. |
In Case T-337/18, orders Laboratoire Pareva to bear its own costs and to pay those incurred by the European Commission, including those incurred in the proceedings for interim measures registered under number T-337/18 R and T-337/18 R II; |
|
4. |
In Case T-347/18, orders Laboratoire Pareva and Biotech3D Ltd & Co. KG to bear their own costs and to pay those incurred by the Commission, including those incurred in the proceedings for interim measures registered under number T-347/18 R, and orders Laboratoire Pareva also to pay the costs incurred in the proceedings for interim measures registered under number T-347/18 R II; |
|
5. |
Orders the French Republic and the European Chemicals Agency (ECHA) to each bear their own costs. |
